| Company | Name | Intervention/treatment | Target | Country | Status | Ref. |
|---|---|---|---|---|---|---|
| Ferring Pharmaceuticals | REBYOTA | Drug | Recurrent Clostridioides difficile infection | Switzerland | FDA approval (November 30, 2022) |
US FDA (2022b) |
| Seres Therapeutics, Inc. | VOWST | Biological | Recurrent Clostridioides difficile infection | United States | FDA approval (April 26, 2023) |
US FDA (2023) |
| Genome & Company | GEN-001 | Drug | Gastric cancer | Republic of Korea | Phase 2 | NIH (2023c) |
| Scioto Biosciences, Inc. | SB-121 | Drug | Autism spectrum disorder | United States | Phase 1 completed | NIH (2022a) |
| Ochsner Health System | RBX7455 | Biological | Hepatic encephalopathy | United States | Phase 2 | NIH (2023d) |
| Enterome | EO2040 | Drug | Colorectal cancer | France | Phase 2 | NIH (2023b) |
| Intralytix, Inc | ShigActiveTM | Biological | Shigellosis | United States | Phase 1/2a | NIH (2023e) |
| Active, not recruiting | ||||||
| 4D Pharma plc | MRx0518 | Drug | Resectable pancreatic cancer | United Kingdom | Phase 1 | NIH (2023a) |